GERMANTOWN, Maryland and HILDEN, Germany, February 13, 2013 /PRNewswire/ --
- Arrangement to facilitate future collaborations in personalized medicine
- Provides framework to develop and commercialize QIAGEN companion diagnostics paired with Lilly medicines in an effort to improve outcomes for individual patients
- Builds on the two companies' recent mutual successes
QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced it has entered into a master collaboration agreement with Eli Lilly and Company (NYSE: LLY) for the development and commercialization of companion diagnostics for pairing with Lilly investigational and approved medicines across all therapeutic areas. The agreement builds on QIAGEN and Lilly's past work together. Companion diagnostics unlock a patient's molecular information in order to guide treatment decisions for specific cancers or other diseases. Financial terms of the agreement are not being disclosed.
The agreement provides a framework for Lilly and QIAGEN to collaborate on future projects - across all of Lilly's therapeutic areas - aimed at bringing to market Lilly medicines paired with QIAGEN diagnostics. It also further underscores QIAGEN's leading position in partnering with global pharmaceutical companies to deliver the benefits of personalized medicine to patients and healthcare providers.
"Tailored therapies are a key component of Lilly's strategy of providing improved outcomes for individual patients. By working with partners like QIAGEN, we are advancing a number of tailored therapeutics in an effort to target the right medicine to the right patient," said Daniel Skovronsky, M.D., Ph.D., vice president, tailored therapeutics, Lilly, and chief executive officer, Avid Radiopharmaceuticals, a wholly-owned subsidiary of Lilly. "This collaboration with QIAGEN extends our capabilities to more quickly and cost-effectively bring innovative new medicines, alongside advanced diagnostics, to patients worldwide who are waiting."
"We have expanded this relationship with Lilly as a result of our ongoing work together," said Dr. Ulrich Schriek, Senior Vice President Global Business Development of QIAGEN. "This agreement lays the groundwork for potential future projects with Lilly in various therapeutic areas and enables significant efficiencies for future development programs by standardizing interfaces and processes between our organizations. Through partnerships like this, QIAGEN offers pharma companies a cost-effective way to maximize the value and benefits of potential new medicines in their pipelines, while also reducing the risks in medicine development."
QIAGEN is at the forefront globally in developing and validating Personalized Healthcare tests that provide physicians with genomic information on each patient to guide the selection of medicines in treating cancer and other diseases. QIAGEN is actively expanding its pipeline of tests for important biomarkers and intends to submit several companion diagnostics for U.S. regulatory approval. Last month, QIAGEN announced submission of its therascreen® EGFR RGQ PCR Kit test to the FDA as a proposed companion diagnostic to guide treatment with a new investigational oncology compound developed by Boehringer Ingelheim. QIAGEN is engaged in more than 15 projects with leading pharmaceutical and biotech companies to co-develop and market companion diagnostics.
QIAGEN and Lilly have previously collaborated on companion diagnostics designed to run on QIAGEN's Rotor-Gene Q system, a component of the QIAsymphony family of automated instruments, which is revolutionizing laboratory workflows. QIAGEN's strategy is to develop FDA-approved diagnostics in the United States for use on this platform.
Photos on Personalized Healthcare are available online for free download at: http://www.qiagen.com/about/press/photoarchive.aspx.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2012, QIAGEN employed approximately 4,000 people in more than 35 locations worldwide. Further information can be found at http://www.qiagen.com/.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products inapplied testing, personalized healthcare, clinical research,proteomics, women's health/HPVtesting andnucleic acid-basedmolecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
Contacts: Public Relations: Dr. Thomas Theuringer Director Public Relations +49-2103-29-11826 +1-240-686-7425 Email: email@example.com http://www.twitter.com/qiagen http://www.qiagen.com/about/press Investor Relations: John Gilardi VP Corporate Communications +49-2103-29-11711 +1-240-686-2222 Peter Vozzo Director, Global Investor Relations +1-240-686-7400 Email: firstname.lastname@example.org
SOURCE Qiagen N.V.